B2M and Thrombocytopenia: Absence of CD56 expression on myeloma cells was found to be associated with higher levels of β2m, Bence Jones proteinuria, renal insufficiency, thrombocytopenia, plasmablastic cell morphology, and shorter OS in 70 multiple myeloma patients who were treated with conventional chemotherapy 33.